Latest Commercial Rollouts News

Thrive Tribe Technologies pivots to modernise and commercialise its WooBoard and REFFIND platforms, targeting enterprise and defence sectors with AI-enabled workforce solutions. A recent A$3 million capital raise supports this shift amid growing revenue and a key exclusive defence distribution deal.

Peppermint Innovation Ltd (ASX:PIL) reported a 171% jump in group revenue for the June quarter, powered by a 577% surge in its Bizmoto revenue and a successful pilot of its QRPh Person-to-Merchant payment platform that tripled monthly transaction values. The company is advancing its ASX reinstatement while expanding its digital payments ecosystem in the Philippines.

4DMedical has secured a pivotal three-year contract with SimonMed Imaging to deploy its CT:VQ™ lung imaging technology across over 170 US outpatient centres, while FY26 revenue rose 23% to $7.2 million on record scan volumes and global expansion.

EVE Health Group has progressed its Libbo pilot clinical study with dosing pushed to Q4 2026 and reported a significant solubility milestone for apixaban, alongside appointing Ben Rohr as CEO to drive commercial growth.

Swift TV Limited has completed its transition from development to commercial rollout, securing Google certification and Netflix approval while expanding contracts across aged care, hospitality, and workforce accommodation.

EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

Rhythm Biosciences bolstered its financial position with a $5.2 million option underwriting while accelerating commercial adoption of its ColoSTAT® colorectal cancer test and advancing geneType™ partnerships internationally in Q4 FY26.

Epiminder has leveraged its $125 million IPO to advance clinical enrolments, boost Medicare reimbursement, and develop its next-generation Minder device, positioning for a commercial launch in early 2028.

Emyria has expanded its Empax clinic network across four states, reporting a 210% revenue increase in FY26 and early clinical success in treatment-resistant depression.

Artrya is advancing its commercial footprint in the US with two health systems now generating revenue and FDA clearance for its Salix Coronary Flow module expected in H2 2026.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.